Abstract: The innovation of combining bazedoxifene with conjugated estrogens provides a new opportunity for women’s health. The finding by the Women’s Health Initiative—that the administration of conjugated equine estrogens alone to women in their 60s who have had hysterectomy results in a decrease in breast cancer incidence and a drop in mortality—was unanticipated but can now be exploited for another gain in women’s health. The issue to be considered is how postmenopausal women can improve their lifestyle to take advantage of conjugated equine estrogens–alone therapy. Food and Drug Administration approval of the combination of bazedoxifene and conjugated estrogens now provides an opportunity for postmenopausal women to reduce hot flashes and to potentially selectively sensitize occult breast cancer cells to the apoptotic actions of estrogen. Clinical trials are proposed to advance women’s health and to reduce the incidence of breast cancer.
From the Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
Received December 13, 2013; revised and accepted January 15, 2014.
The views and opinions of the author do not reflect those of the US Army or the Department of Defense.
Funding/support: This work was supported by the Department of Defense Breast Program (under award number W81XWH-06-1-0590 Center of Excellence), the Susan G. Komen for the Cure Foundation (under award number SAC100009), and the Lombardi Comprehensive Cancer Center Support Grant (core grant NIH P30 CA051008).
Financial disclosure/conflicts of interest: None reported.
Address correspondence to: V. Craig Jordan, OBE, PhD, DSc, FMedSci, Georgetown University Medical Center, Suite E501, Research Building, 3970 Reservoir Road NW, Washington, DC 20057. E-mail: firstname.lastname@example.org